Skip to Content

Label Changes for:

Alimta (pemetrexed for injection) for intravenous use, 100 mg and 500 mg vials

September 2013

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)


September 2013


Postmarketing Experience
  • These reactions occurred with Alimta when used as a single-agent and in combination therapies.
  • Blood and Lymphatic System — immune-mediated hemolytic anemia